Literature DB >> 32171053

Cardiorenal risk reduction guidance in diabetes: can we reach consensus?

Naveed Sattar1, John Jv McMurray2, Alice Yy Cheng3.   

Abstract

Entities:  

Year:  2020        PMID： 32171053     DOI： 10.1016/S2213-8587(20)30062-0

Source DB:  PubMed          Journal:  Lancet Diabetes Endocrinol        ISSN： 2213-8587            Impact factor:   32.069


× No keyword cloud information.
  4 in total

1.  Estimated Life-Years Gained Free of New or Recurrent Major Cardiovascular Events With the Addition of Semaglutide to Standard of Care in People With Type 2 Diabetes and High Cardiovascular Risk.

Authors:  Jan Westerink; Kasper Sommer Matthiessen; Solomon Nuhoho; Udi Fainberg; Michael Lyng Wolden; Helena Bleken Østergaard; Frank Visseren; Naveed Sattar
Journal:  Diabetes Care       Date:  2022-05-01       Impact factor: 17.152

2.  Effect of Dapagliflozin in DAPA-HF According to Background Glucose-Lowering Therapy.

Authors:  Kieran F Docherty; Pardeep S Jhund; Olof Bengtsson; David L DeMets; Silvio E Inzucchi; Lars Køber; Mikhail N Kosiborod; Anna Maria Langkilde; Felipe A Martinez; Marc S Sabatine; Mikaela Sjöstrand; Scott D Solomon; John J V McMurray
Journal:  Diabetes Care       Date:  2020-09-02       Impact factor: 19.112

3.  Network Pharmacology-Based Identification of the Mechanisms of Shen-Qi Compound Formula in Treating Diabetes Mellitus.

Authors:  Zhipeng Hu; Maoyi Yang; Liangjun Yang; Chunguang Xie; Hong Gao; Xiaoxu Fu; Hongyan Xie; Ya Liu
Journal:  Evid Based Complement Alternat Med       Date:  2020-06-04       Impact factor: 2.629

4.  The efficacy and safety of Yuxingcao eye drops in the treatment of COVID-19 conjunctivitis: A protocol for a systematic review.

Authors:  Jiajun Wu; Liqu Pu; Hui Zhou; Wenjia Qu; Dandan Zhao; Chunmeng Liu; Xuewen Dong; Fuwen Zhang
Journal:  Medicine (Baltimore)       Date:  2020-12-04       Impact factor: 1.817
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.